United Capital Management of KS Inc. Buys 2,588 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

United Capital Management of KS Inc. lifted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 1.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 173,115 shares of the exchange traded fund’s stock after acquiring an additional 2,588 shares during the quarter. SPDR S&P Biotech ETF accounts for 2.8% of United Capital Management of KS Inc.’s investment portfolio, making the stock its 8th largest position. United Capital Management of KS Inc. owned 0.23% of SPDR S&P Biotech ETF worth $15,591,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Golden State Wealth Management LLC acquired a new stake in shares of SPDR S&P Biotech ETF in the 4th quarter valued at $29,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of SPDR S&P Biotech ETF in the 4th quarter valued at $29,000. Avior Wealth Management LLC raised its holdings in shares of SPDR S&P Biotech ETF by 393.6% in the 4th quarter. Avior Wealth Management LLC now owns 385 shares of the exchange traded fund’s stock valued at $35,000 after purchasing an additional 307 shares in the last quarter. Tidemark LLC raised its holdings in shares of SPDR S&P Biotech ETF by 101.5% in the 3rd quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock valued at $39,000 after purchasing an additional 199 shares in the last quarter. Finally, Bank of Jackson Hole Trust acquired a new stake in shares of SPDR S&P Biotech ETF in the 4th quarter valued at $43,000.

SPDR S&P Biotech ETF Trading Up 1.3 %

Shares of XBI opened at $87.13 on Friday. The firm’s fifty day simple moving average is $90.06 and its 200-day simple moving average is $94.86. The firm has a market capitalization of $5.75 billion, a price-to-earnings ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a twelve month low of $81.14 and a twelve month high of $105.47.

About SPDR S&P Biotech ETF

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.